JP2021518159A5 - - Google Patents

Info

Publication number
JP2021518159A5
JP2021518159A5 JP2020573079A JP2020573079A JP2021518159A5 JP 2021518159 A5 JP2021518159 A5 JP 2021518159A5 JP 2020573079 A JP2020573079 A JP 2020573079A JP 2020573079 A JP2020573079 A JP 2020573079A JP 2021518159 A5 JP2021518159 A5 JP 2021518159A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
letters represent
lna
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020573079A
Other languages
English (en)
Japanese (ja)
Other versions
JP7318166B2 (ja
JP2021518159A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022351 external-priority patent/WO2019178411A1/en
Publication of JP2021518159A publication Critical patent/JP2021518159A/ja
Publication of JP2021518159A5 publication Critical patent/JP2021518159A5/ja
Application granted granted Critical
Publication of JP7318166B2 publication Critical patent/JP7318166B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573079A 2018-03-14 2019-03-14 マイクロrna22の阻害剤 Active JP7318166B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642934P 2018-03-14 2018-03-14
US62/642,934 2018-03-14
PCT/US2019/022351 WO2019178411A1 (en) 2018-03-14 2019-03-14 Inhibitors of micro-rna 22

Publications (3)

Publication Number Publication Date
JP2021518159A JP2021518159A (ja) 2021-08-02
JP2021518159A5 true JP2021518159A5 (https=) 2022-03-16
JP7318166B2 JP7318166B2 (ja) 2023-08-01

Family

ID=67908026

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573079A Active JP7318166B2 (ja) 2018-03-14 2019-03-14 マイクロrna22の阻害剤
JP2020549635A Pending JP2021518841A (ja) 2018-03-14 2019-03-14 マイクロrnaと肥満症

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020549635A Pending JP2021518841A (ja) 2018-03-14 2019-03-14 マイクロrnaと肥満症

Country Status (12)

Country Link
US (2) US11753639B2 (https=)
EP (2) EP3765610A4 (https=)
JP (2) JP7318166B2 (https=)
KR (2) KR20200131287A (https=)
CN (2) CN112119159B (https=)
AU (2) AU2019234917B2 (https=)
BR (2) BR112020018705A2 (https=)
CA (2) CA3093572A1 (https=)
ES (1) ES3001019T3 (https=)
RU (2) RU2020131372A (https=)
SG (2) SG11202008925VA (https=)
WO (2) WO2019178410A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200131287A (ko) 2018-03-14 2020-11-23 베스 이스라엘 데코니스 메디칼 센터 마이크로-rna 22의 억제제
CN110609142A (zh) * 2019-10-09 2019-12-24 广州医科大学附属第二医院 一种检测外周血fto蛋白与自身调控元件结合能力的方法与应用
CN115029347B (zh) * 2022-05-11 2024-02-20 珠海中科先进技术研究院有限公司 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒
CN116082447A (zh) * 2022-09-09 2023-05-09 湖南大学 一种多肽及其制备方法
CN117304258B (zh) * 2022-09-09 2024-09-24 湖南大学 一种多肽的用途
EP4353823A1 (en) * 2022-10-12 2024-04-17 Resalis Therapeutics S.r.l. Inhibitors of micro-rna 22

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
JP2002516256A (ja) 1998-05-26 2002-06-04 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 二環式糖成分を有する新規ヌクレオシド
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
EP2302055B1 (en) * 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
KR101485071B1 (ko) * 2005-12-12 2015-01-26 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 마이크로 rna를 이용한 근육 세포 증식 및 분화 조절방법과 근육 세포 치료방법 및 유전자 발현 억제방법그리고 마이크로 rna 분자의 발현용 벡터와 이를 이용한키트 및 미오사이트
AU2013254923A1 (en) * 2006-04-03 2013-11-28 Santaris Pharma A/S Pharmaceutical compositions comprising anti-miRNA antisense oligonucleotide
EP2007888A2 (en) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2623599B1 (en) * 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
EP2419537B1 (en) * 2009-04-13 2014-01-29 Somagenics, Inc. Methods and compositions for detection of small rnas
SG176716A1 (en) * 2009-06-08 2012-01-30 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
UY33807A (es) * 2010-12-17 2012-07-31 Sanofi Sa miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis
CA2832899A1 (en) 2011-04-12 2012-10-18 Beth Israel Deaconess Medical Center, Inc. Micro-rna inhibitors and their uses in disease
JP6092655B2 (ja) * 2012-02-23 2017-03-08 善基 村上 テスト体液サンプルの分類方法
US9034839B2 (en) 2012-04-20 2015-05-19 Aptamir Therapeutics, Inc. miRNA modulators of thermogenesis
WO2013181613A1 (en) * 2012-05-31 2013-12-05 Research Development Foundation Mirna for the diagnosis and treatment of autoimmune and inflammatory disease
CN107236735B (zh) * 2012-06-21 2019-11-08 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
US9822358B2 (en) 2013-10-18 2017-11-21 Beth Israel Deaconess Medical Center Treatment of cancers with micro-RNA inhibitors
CA2935426C (en) * 2014-01-30 2023-07-25 F. Hoffmann-La Roche Ag Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
WO2016127002A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
WO2016149358A1 (en) * 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle
WO2017187426A1 (en) * 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN107432933A (zh) * 2017-07-13 2017-12-05 中南大学湘雅三医院 miR‑22作为靶位点在制备膀胱癌的化疗增敏治疗药物中的应用
WO2019053235A1 (en) * 2017-09-15 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
KR20200131287A (ko) 2018-03-14 2020-11-23 베스 이스라엘 데코니스 메디칼 센터 마이크로-rna 22의 억제제
WO2019217907A1 (en) * 2018-05-11 2019-11-14 The Regents Of The University Of California Methods and compositions for the treatment of hepatic and metabolic diseases

Similar Documents

Publication Publication Date Title
JP2021518159A5 (https=)
Mundt et al. Complete nucleotide sequences of 5′-and 3′-noncoding regions of both genome segments of different strains of infectious bursal disease virus
Lin et al. Sequence comparisons of a highly virulent infectious bursal disease virus prevalent in Japan
Soto‐Rifo et al. The role of the DEAD‐box RNA helicase DDX3 in mRNA metabolism
Jeong et al. Characterization of the DNA nucleotide sequences in the genome of red sea bream iridoviruses isolated in Korea
Dodson et al. Specialized nucleoprotein structures at the origin of replication of bacteriophage lambda: localized unwinding of duplex DNA by a six-protein reaction.
JP2023543803A5 (https=)
JP2024530487A5 (https=)
EP4089175A1 (en) Genome engineering with type i crispr systems in eukaryotic cells
JP2021534798A5 (https=)
JP2022519761A5 (https=)
Klovins et al. A long-range interaction in Qβ RNA that bridges the thousand nucleotides between the M-site and the 3′ end is required for replication
JP2019536425A5 (https=)
JP2024511163A5 (https=)
JP2015532097A5 (https=)
JP2012136542A5 (https=)
JP2008533988A5 (https=)
Prevelige et al. Building the machines: scaffolding protein functions during bacteriophage morphogenesis
Goodman et al. The nucleotide sequence at the 5′-terminus of the Qβ RNA minus strand
JP2023511991A5 (https=)
RU2022103641A (ru) Искусственная модификация генома для регуляции экспрессии гена
JP2021505129A5 (https=)
RU2020131372A (ru) ИНГИБИТОРЫ микроРНК 22
JP2024511131A5 (https=)
JP2021522825A5 (https=)